TNFR1 is essential for CD40, but not for lipopolysaccharide-induced sickness behavior and clock gene dysregulation

Brain, Behavior, and Immunity

Volumn 25, Issue 3, 2011, Pages 434-442

  Taraborrelli, Cornelia ^a   Palchykova, Svitlana ^a   Tobler, Irene ^a   Gast, Heidemarie ^b   Birchler, Thomas ^a   Fontana, Adriano ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

CD40; Clock gene regulation; Cytokines; Immunity; LPS; Sickness behavior

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; NUCLEAR RECEPTOR NR1D1; PER2 PROTEIN; PER3 PROTEIN; PROTEIN BMAL1; TRANSCRIPTION FACTOR CLOCK; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; E BOX ELEMENT; GENE EXPRESSION; ILLNESS BEHAVIOR; IMMUNE RESPONSE; LOCOMOTION; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CHROMATIN IMMUNOPRECIPITATION; CLOCK PROTEINS; CYTOKINES; GENE EXPRESSION REGULATION; ILLNESS BEHAVIOR; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; T-LYMPHOCYTES;

EID: 79551687660     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.11.001     Document Type: Article

References (52)

1. Advani R., Forero-Torres A., Furman R.R., Rosenblatt J.D., Younes A., Ren H., Harrop K., Whiting N., Drachman J.G. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 2009, 27:4371-4377.
2. Balasa B., Krahl T., Patstone G., Lee J., Tisch R., McDevitt H.O., Sarvetnick N. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 1997, 159:4620-4627.
3. Bluthe R.M., Laye S., Michaud B., Combe C., Dantzer R., Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur. J. Neurosci. 2000, 12:4447-4456.
4. Boggio V.I., Castrillon P.O., Perez Lloret S., Riccio P., Esquifino A.I., Cardinali D.P., Cutrera R.A. Cerebroventricular administration of interferon-gamma modifies locomotor activity in the golden hamster. Neurosignals 2003, 12:89-94.
5. Burgos P.I., Alarcon G.S., McGwin G., Crews K.Q., Reveille J.D., Vila L.M. Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum. 2009, 61:1179-1186.
6. Cavadini G., Petrzilka S., Kohler P., Jud C., Tobler I., Birchler T., Fontana A. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc. Natl. Acad. Sci. USA 2007, 104:12843-12848.
7. Danese S., Sans M., Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 2004, 53:1035-1043.
8. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
9. De La Garza R. Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci. Biobehav. Rev. 2005, 29:761-770.
10. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
11. Durie F.H., Fava R.A., Foy T.M., Aruffo A., Ledbetter J.A., Noelle R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993, 261:1328-1330.
12. Elgueta R., Benson M.J., de Vries V.C., Wasiuk A., Guo Y., Noelle R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 2009, 229:152-172.
13. Etchegaray J.P., Lee C., Wade P.A., Reppert S.M. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature 2003, 421:177-182.
14. Farahani P., Levine M., Gaebel K., Wang E.C., Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 2006, 33:665-670.
15. Furman R.R., Forero-Torres A., Shustov A., Drachman J.G. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 2010, 51:228-235.
16. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 1998, 16:111-135.
17. Haller D., Holt L., Kim S.C., Schwabe R.F., Sartor R.B., Jobin C. Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J. Biol. Chem. 2003, 278:23851-23860.
18. Hart B.L. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 1988, 12:123-137.
19. Hastings M.H., Reddy A.B., Maywood E.S. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat. Rev. Neurosci. 2003, 4:649-661.
20. Howard L.M., Miga A.J., Vanderlugt C.L., Dal Canto M.C., Laman J.D., Noelle R.J., Miller S.D. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 1999, 103:281-290.
21. Hussein, M., Berenson, J.R., Niesvizky, R., Munshi, N., Matous, J., Sobecks, R., Harrop, K., Drachman, J.G., Whiting, N., 2010. A phase 1 multidose study of dacetuzumab (SGN-40; humanized anti-CD40 mAb) in patients with multiple myeloma. Haematologica.
22. Imeri L., Opp M.R. How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 2009, 10:199-210.
23. Katz P., Yelin E., Patel V., Huang X.Y., Chiou C.F. Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists. Arthritis Rheum. 2009, 61:593-599.
24. King D.P., Takahashi J.S. Molecular genetics of circadian rhythms in mammals. Annu. Rev. Neurosci. 2000, 23:713-742.
25. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002, 25:154-159.
26. Kwak Y., Lundkvist G.B., Brask J., Davidson A., Menaker M., Kristensson K., Block G.D. Interferon-gamma alters electrical activity and clock gene expression in suprachiasmatic nucleus neurons. J. Biol. Rhythms 2008, 23:150-159.
27. Leon L.R., Kozak W., Peschon J., Kluger M.J. Exacerbated febrile responses to LPS, but not turpentine, in TNF double receptor-knockout mice. Am. J. Physiol. 1997, 272:R563-569.
28. Lichtenstein G.R., Bala M., Han C., DeWoody K., Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm. Bowel Dis. 2002, 8:237-243.
29. Liu Z., Geboes K., Colpaert S., Overbergh L., Mathieu C., Heremans H., de Boer M., Boon L., D'Haens G., Rutgeerts P., Ceuppens J.L. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions. J. Immunol. 2000, 164:6005-6014.
30. Majde J.A., Krueger J.M. Links between the innate immune system and sleep. J. Allergy Clin. Immunol. 2005, 116:1188-1198.
31. Mohan C., Shi Y., Laman J.D., Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 1995, 154:1470-1480.
32. Moreland L.W., Genovese M.C., Sato R., Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum. 2006, 55:287-293.
33. Ohdo S., Koyanagi S., Suyama H., Higuchi S., Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat. Med. 2001, 7:356-360.
34. Okada K., Yano M., Doki Y., Azama T., Iwanaga H., Miki H., Nakayama M., Miyata H., Takiguchi S., Fujiwara Y., Yasuda T., Ishida N., Monden M. Injection of LPS causes transient suppression of biological clock genes in rats. J. Surg. Res. 2008, 145:5-12.
35. Palin K., Bluthe R.M., McCusker R.H., Levade T., Moos F., Dantzer R., Kelley K.W. The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFalpha-induced sickness behavior. Psychopharmacology (Berlin) 2009, 201:549-556.
36. Petrzilka S., Taraborrelli C., Cavadini G., Fontana A., Birchler T. Clock gene modulation by TNF-alpha depends on calcium and p38 MAP kinase signaling. J. Biol. Rhythms 2009, 24:283-294.
37. Preitner N., Damiola F., Lopez-Molina L., Zakany J., Duboule D., Albrecht U., Schibler U. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 2002, 110:251-260.
38. Qin H., Wilson C.A., Roberts K.L., Baker B.J., Zhao X., Benveniste E.N. IL-10 inhibits lipopolysaccharide-induced CD40 gene expression through induction of suppressor of cytokine signaling-3. J. Immunol. 2006, 177:7761-7771.
39. Reppert S.M., Weaver D.R. Coordination of circadian timing in mammals. Nature 2002, 418:935-941.
40. Ripperger J.A., Schibler U. Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat. Genet. 2006, 38:369-374.
41. Ripperger J.A., Shearman L.P., Reppert S.M., Schibler U. CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev. 2000, 14:679-689.
42. Schibler U. The 2008 Pittendrigh/Aschoff lecture: peripheral phase coordination in the mammalian circadian timing system. J. Biol. Rhythms 2009, 24:3-15.
43. Schibler U., Sassone-Corsi P. A web of circadian pacemakers. Cell 2002, 111:919-922.
44. Shang Y., Hu X., DiRenzo J., Lazar M.A., Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103:843-852.
45. Shinohara A., Koyanagi S., Hamdan A.M., Matsunaga N., Aramaki H., Ohdo S. Dosing schedule-dependent change in the disruptive effects of interferon-alpha on the circadian clock function. Life Sci. 2008, 83:574-580.
46. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:578-582.
47. Teeling J.L., Felton L.M., Deacon R.M., Cunningham C., Rawlins J.N., Perry V.H. Sub-pyrogenic systemic inflammation impacts on brain and behavior, independent of cytokines. Brain Behav. Immun. 2007, 21:836-850.
48. Tench C.M., McCurdie I., White P.D., D'Cruz D.P. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000, 39:1249-1254.
49. Tollner B., Roth J., Storr B., Martin D., Voigt K., Zeisberger E. The role of tumor necrosis factor (TNF) in the febrile and metabolic responses of rats to intraperitoneal injection of a high dose of lipopolysaccharide. Pflugers Arch. 2000, 440:925-932.
50. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
51. van Hoogmoed, D., Fransen, J., Bleijenberg, G., van Riel, P., 2010. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford).
52. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000, 96:2917-2924.